New York, Sep 12 (IANS) The risk of type 2 diabetes is more than halved by weekly injections of the new obesity drug semaglutide, which was recently approved in the US and has been provisionally approved in England, says a new study. The researchers of the study, to be presented at the annual meeting of the European Association for the Study ...

Read More »